PFMOSF
TNGX icon

Philadelphia Financial Management of San Francisco’s Tango Therapeutics TNGX Stock Holding History

Philadelphia Financial Management of San Francisco’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,291
Closed -$295K – 68
2025
Q4 		$295K Buy
+33,291
New +$287K 0.03% 57

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Philadelphia Financial Management of San Francisco's TNGX Position: Q1 2026 in Review

Philadelphia Financial Management of San Francisco sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 33,291 shares — an estimated $295K sold.

Philadelphia Financial Management of San Francisco first reported a position in TNGX in Q4 2025 and held it in 1 quarter. The position peaked at $295K in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Philadelphia Financial Management of San Francisco reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Philadelphia Financial Management of San Francisco sold 33,291 Tango Therapeutics shares in Q1 2026, an estimated $295K.
  • Philadelphia Financial Management of San Francisco first reported a position in Tango Therapeutics in Q4 2025 and held it in 1 quarter.
  • Philadelphia Financial Management of San Francisco's Tango Therapeutics position peaked at $295K in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Philadelphia Financial Management of San Francisco's 13F filing for Q1 2026, filed 14 May 2026.